Psilocybin for Addiction: Tobacco and Alcohol Clinical Evidence
About This Video
Clinical evidence overview for psilocybin in addiction treatment — focusing on Matthew Johnson's 2014 tobacco cessation study (80% abstinence at 6 months) and Michael Bogenschutz's 2022 NYU alcohol use disorder RCT (83% reduction in heavy drinking days).
Both findings are presented with appropriate context: the tobacco study was a pilot (n=15) without a control group; its magnitude demands replication but hasn't been replicated at scale yet. The NYU alcohol RCT is the most rigorous design available and its results are compelling.
The mechanism is covered: addiction involves entrenched self-narrative patterns ('I am a smoker') mediated by the default mode network. Psilocybin's disruption of these patterns creates a perspective-shift that multiple participants describe as suddenly seeing the addiction from outside — which the neuroplasticity window then allows to be consolidated through behavioral work.
Key Takeaways
- Johnson's tobacco pilot (n=15) showed 80% abstinence at 6 months — nearly double the best pharmacotherapy.
- Bogenschutz's alcohol RCT (n=93) showed 83% reduction in heavy drinking days vs. 51% placebo.
- The mystical experience correlation: higher mystical experience ratings correlate with better addiction outcomes.
- The mechanism involves DMN disruption of addicted self-narrative and post-session neuroplasticity for behavioral consolidation.
- A larger randomized tobacco trial comparing psilocybin to nicotine patch is ongoing at Johns Hopkins.
Dive Deeper
Continue exploring this topic on LearnShrooms: